Argenx SE (ARGX) has made significant strides in Q3 and Q4 of 2024 as highlighted in its financial results and business updates. A notable achievement is securing
approval for VYVGART Hytrulo from the US FDA and China's NMPA for treating
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). This along with disease-specific data revealings have led to its stock value soaring to an all-time high of $630.4, sparking investor interest. The firm's
global collaboration with Halozyme for
ENHANZE and Zai Lab have also added wind to its sails. Meanwhile, its alliance with Steritas is meant to advance evidence for novel steroid-sparing therapeutics. Maintaining a keen eye on the future, Argenx is planning to participate in multiple
upcoming investor conferences and has been announced to unveil its '
Vision 2030: Taking Breakthrough'. Notably, Argenx’s Strong Q2 Sales have reinvigorated its clinical plans for Vyvgart, which is set to launch in ten indications by 2030.
argenx News Analytics from Thu, 14 Mar 2024 07:00:00 GMT to Sat, 21 Dec 2024 07:54:48 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor -6
